AMPE : Summary for Ampio Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets open in 8 hrs 27 mins

Ampio Pharmaceuticals, Inc. (AMPE)


NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
0.81+0.00 (+0.21%)
At close: 4:02PM EDT
People also watch
ACRXANTHMRNSALIMAVEO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.81
Open0.81
Bid0.00 x
Ask0.00 x
Day's Range0.81 - 0.85
52 Week Range0.59 - 4.32
Volume156,346
Avg. Volume274,025
Market Cap46.56M
Beta0.62
PE Ratio (TTM)-1.65
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire9 hours ago

    Update - Ampio Pharmaceuticals Provides Corporate Update

    ENGLEWOOD, Colo., March 22, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), a leader in the development of Ampion™, a low molecular weight fraction of human serum albumin with anti-inflammatory properties, today announced that it is re-issuing its previous release that was made on March 20, 2017 to incorporate certain disclosures that are required under the NYSE MKT Company Guide Sections 401(h) and 610(b). Included below are these additional disclosures along with the previously disclosed update of corporate activities. As stated in a press release dated February 27, 2017, having recently concluded a successful series of meetings with the US Food and Drug Administration ("FDA"), Ampio is preparing to initiate what is anticipated to be the final pivotal trial of Ampion™ to treat the severe pain associated with Kellgren-Lawrence grade 4 osteoarthritis of the knee ("OAK").

  • PR Newswire3 days ago

    Ampio Pharmaceuticals Provides Corporate Update

    ENGLEWOOD, Colo., March 20, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), a leader in the development of Ampion™, a low molecular weight fraction of human serum albumin with anti-inflammatory properties, announced an update of corporate activities.  As stated in a press release dated February 27, 2017, having recently concluded a successful series of meetings with the US Food and Drug Administration ("FDA"), Ampio is preparing to initiate what is anticipated to be the final pivotal trial of Ampion™ to treat the severe pain associated with Kellgren-Lawrence grade 4 osteoarthritis of the knee ("OAK"). As recommended by the FDA, the proposed primary endpoint for this study follows OARSI guidance, utilizing the OMERACT-OARSI responder rate. In addition, Ampio plans to advance all necessary Biologic License Application (BLA) activities in parallel to expedite the path to potential FDA approval.

  • PR Newswire22 days ago

    Ampio Hosting Conference Call Tuesday, March 7, 4:30pm EST

    ENGLEWOOD, Colo., March 1, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT:  AMPE) will host an investor conference call Tuesday, March 7 th at 4:30 pm EST. Participants are invited to dial-in ...